Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

Learn how antibody-drug conjugates are advancing therapies for non-cancer conditions, unlocking new possibilities in ...

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, announced the ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)'s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized by the European Commission on June 3, 2025, for newly diagnosed adult ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the chemotherapy regimen for adults with newly diagnosed Stage IIb Hodgkin's ...

ADCETRIS is an antibody-drug conjugate targeting CD30, a marker of Hodgkin lymphoma, and has six distinct indications previously approved in the EU.

ADCETRIS (brentuximab vedotin) Important Safety Information (European Union) Please refer to Summary of Product Characteristics (SmPC) before prescribing.

OSAKA, Japan & CAMBRIDGE, Mass., June 03, 2025--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, ...

The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary ...

Takeda(TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS ® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and ...